argenx to Present at Upcoming Investor Conferences
30 8월 2023 - 2:00PM
August
30,
2023Amsterdam,
the Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases, today announced
that members of management will participate in several upcoming
investor conferences in September:
- Citi's
18th Annual BioPharma Conference. Fireside chat on
Wednesday, September 6, 2023 at 4:20 p.m. ET in Boston, MA.
- Wells
Fargo Healthcare Conference. Fireside chat on Thursday,
September 7, 2023 at 8:00 a.m. ET in Boston, MA.
- Morgan
Stanley 21st Annual Global Healthcare Conference. Fireside
chat on Monday, September 11, 2023 at 12:55 p.m. ET in New York,
NY.
Additional information regarding these events will be available
on the Investors section of the argenx website at
argenx.com/investors.
About argenx
argenx is a global immunology company committed to improving the
lives of people suffering from severe autoimmune diseases.
Partnering with leading academic researchers through its Immunology
Innovation Program (IIP), argenx aims to translate immunology
breakthroughs into a world-class portfolio of novel antibody-based
medicines. argenx developed and is commercializing the first
approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan,
Israel, the EU, the UK and China. The Company is evaluating
efgartigimod in multiple serious autoimmune diseases and advancing
several earlier stage experimental medicines within its therapeutic
franchises. For more information, visit www.argenx.com and
follow us on LinkedIn, Twitter, and Instagram.
For further information, please contact:
Media:
Erin Murphyemurphy@argenx.com
Investors:
Alexandra Roy (US)aroy@argenx.com
Lynn Elton (EU)lelton@argenx.com
Argen X (EU:ARGX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Argen X (EU:ARGX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024